Ginkgo bioworks acquires circularis to strengthen capabilities in cell and gene therapy

Boston , oct. 4, 2022 /prnewswire/ -- ginkgo bioworks (nyse: dna), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of circularis, a biotechnology company with a proprietary circular rna and promoter screening platform. when circularized, rna is much longer-lived in cells, improving its robustness as a potential therapeutic modality.
DNA Ratings Summary
DNA Quant Ranking